SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Kirk's Market Thoughts
COHR 185.70+2.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
jpdunwell
Kirk ©
To: Kirk © who wrote (12047)10/2/2021 4:42:10 PM
From: Logain Ablar2 Recommendations  Read Replies (3) of 26731
 
Hi Kirk:

Asking a pharma company to do a phase II / III trial for a drug like Ivermectin, that is off patent and is inexpensive to manufacture and distribute is problematic. It is actually disingenuous in the sense the FDA and CDC (think Fauci) know a Company won't do a trial unless it is funded by a 3rd party (government or private foundation) but they just point out there is no phase III. They will never recoup the invested costs as generic's will take the market once approved. We have Merck who first developed Ivermectin (my script is from Edenbridge Pharmaceuticals) now coming out with a potential competing product as well as Pfizer. Somehow I don't think those products will be $10 for a 5 day script.

What you've had in the U.S. is many of the MD's who are not reimbursed by the insurers (like those who treat Tick Borne Diseases) have embraced Ivermectin due to what they've read and seen from their peers and colleague's.

The best site I've found for this is below. Then to add Ivermectin "may" inhibit some colorectal cancer's. 2nd link.

Home - FLCCC | Front Line COVID-19 Critical Care Alliance (covid19criticalcare.com)

frontiersin.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News